The First Few Hundred Cases for Coronavirus Disease 2019 (COVID-19) in Colombia
,
Abstract
Background: SARS-CoV-2 virus is the causative agent of COVID-19 disease. It is essential to understand the epidemiological characteristics of the first few cases in each country. This study aimed to describe the geographical distribution, and temporal appearance of the first few hundred cases in Colombia.
Methods: This observational study was conducted to review the literature and key documentary information from public health institutions, websites and news reports were examined.
Results: The first few 100 cases for COVID-19 were confirmed in Colombia. According to sex, men with 54% predominate, the most affected age group was 20 to 29 yr old (26%), 9% of the cases required hospitalization and no deaths were reported. Most of the confirmed subjects were from the departments of Cundinamarca. To date, most cases are imported (63%), especially from Spain.
Conclusion: The COVID-19 pandemic puts in evidence the lack of understanding, prevention and contention power of the different countries around the world is not as good as it could be. Politics must not affect the different proposed measures.
1. Wu F, Zhao S, Yu B et al (2020). A new coronavirus associated with human respiratory disease in China. Nature, 79 (7798): 265-69.
2. WHO (2020). Situation report 58. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports2020.
3. Zhou P, Yang X-L, Wang X-G et al (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579 (7798): 270-73.
4. Gao QY, Chen YX, Fang JY (2020). 2019 novel coronavirus infection and gastrointestinal tract. J Dig Dis, 21: 125-126.
5. WHO (2020). Director-General's remarks at the media briefing on 2019-nCoV. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020
6. Drosten C, Günther S, Preiser W et al (2003). Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med, 348 (20): 1967-76.
7. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen K-Y (2016). Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug, 15 (5): 327-347.
8. Kuba K, Imai Y, Rao S et al (2005). A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nat Med, 11 (8): 875-9.
9. Li W, Moore MJ, Vasilieva N et al (2003). Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature, 426 (6965): 450-4.
10. Gurwitz D (2020). Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res, 1-4.
11. Wang D, Hu B, Hu C et al (2020). Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA, 201585.
12. Chen N, Zhou M, Dong X et al (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 395 (10223): 507-13.
13. Chan JF-W, Yuan S, Kok K-H et al (2020). A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, 395 (10223 ): 514-23.
14. Zu ZY, Jiang MD, Xu PPet al (2020). Coronavirus Disease 2019 (COVID-19): A Perspective from China. Radiology, 200490.
15. Dong Y, Mo X, Hu Y et al (2020). Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. Pediatrics, e20200702.
16. Liu J, Zheng X, Tong Q et al (2020). Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS‐CoV, MERS‐CoV, and 2019‐nCoV. J Med Virol, 92(5): 491-4.
17. Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J (2020). The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med, 27(2): taaa021.
18. Society of Pediatrics CMA (2020). Recommendations for the diagnosis, prevention and control of the 2019 novel coronavirus infection in children (first interim edition). Zhonghua Er Ke Za Zhi, 58(0): E004.
19. Zhou S, Wang Y, Zhu T, Xia L (2020). CT Features of Coronavirus Disease 2019 (COVID-19) Pneumonia in 62 Patients in Wuhan, China. AJR Am J Roentgeno,5:1-8.
20. He F, Deng Y, Li W (2020). Coronavirus Disease 2019 (COVID-19): What we know? J Med Virol, 1-7.
21. Lu X, Zhang L, Du H et al (2020). SARS-CoV-2 Infection in Children. N Engl J Med, 2005073.
22. Worcester S (2020). COVID-19 Characteristics Differ in Children vs Adults Available from: https://www.medscape.com/viewarticle/926805
23. Gortazar C, Reperant LA, Kuiken T et al (2014). Crossing the interspecies barrier: opening the door to zoonotic pathogens. PLoS Pathog, 10 (6): e1004129.
24. Rosenberg R (2015). Detecting the emergence of novel, zoonotic viruses pathogenic to humans. Cell Mol Life Sci,72 (6): 1115-25.
25. Brown C (2004). Emerging zoonoses and pathogens of public health significance--an overview. Rev Sci Tech, 23 (2): 435-42.
26. CDC (2017). One Health Basics. Available from: https://www.cdc.gov/onehealth/basics/index.html2017
27. CDC (2016). History. Available from: https://www.cdc.gov/onehealth/basics/history/index.html
28. Bidaisee S, Macpherson CNL (2014). Zoonoses and One Health: A Review of the Literature. J Parasitol Res, 2014: 874345.
29. Wrapp D, Wang N, Corbett KS et al (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 367 (6483): 1260-3.
30. Shi H, Han X, Jiang N et al (2020). Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis, 20: 425-34.
31. Baden LR, Rubin EJ (2020). Covid-19 — The Search for Effective Therapy. N Engl J Med.
32. Gao J, Tian Z, Yang X (2020). Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends, 14 (1): 72-3.
33. Gallardo Solarte K, Benavides Acosta FP, Rosales Jiménez R (2016). Costos de la enfermedad crónica no transmisible: la realidad colombiana. Rev Cienc Salud, 14 (1): 103-14.
34. Maldonado JM (2009). Ciudades y contaminación ambiental. Revista de ingeniería, 30: 66-71.
35. Barrera-Dussán N, Fierro-Parra EP, Puentes-Fierro LY, Ramos-Castañeda JA (2018). Prevalencia y determinantes sociales de malnutrición en menores de 5 años afiliados al Sistema de Selección de Beneficiarios para Programas Sociales (SISBEN) del área urbana del municipio de Palermo en Colombia, 2017. Universidad y Salud, 20 (3): 236-46.
36. Bernal O, Barbosa S (2015). La nueva reforma a la salud en Colombia: el derecho, el aseguramiento y el sistema de salud. Salud Pública Mex, 57 (5): 433-40.
37. Olivera MJ, Porras Villamil JF, Toquica Gahona CC, Rodríguez Hernández JM (2018). Barriers to Diagnosis Access for Chagas Disease in Colombia. J Parasitol Res, 2018: 4940796.
38. Holshue ML, DeBolt C, Lindquist S et al (2020). First case of 2019 novel coronavirus in the United States. N Engl J Med, 382 (10): 929-36.
39. Lim J, Jeon S, Shin H-Y et al (2020). Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci, 35 (6): e79.
2. WHO (2020). Situation report 58. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports2020.
3. Zhou P, Yang X-L, Wang X-G et al (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579 (7798): 270-73.
4. Gao QY, Chen YX, Fang JY (2020). 2019 novel coronavirus infection and gastrointestinal tract. J Dig Dis, 21: 125-126.
5. WHO (2020). Director-General's remarks at the media briefing on 2019-nCoV. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020
6. Drosten C, Günther S, Preiser W et al (2003). Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med, 348 (20): 1967-76.
7. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen K-Y (2016). Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug, 15 (5): 327-347.
8. Kuba K, Imai Y, Rao S et al (2005). A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nat Med, 11 (8): 875-9.
9. Li W, Moore MJ, Vasilieva N et al (2003). Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature, 426 (6965): 450-4.
10. Gurwitz D (2020). Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res, 1-4.
11. Wang D, Hu B, Hu C et al (2020). Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA, 201585.
12. Chen N, Zhou M, Dong X et al (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 395 (10223): 507-13.
13. Chan JF-W, Yuan S, Kok K-H et al (2020). A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, 395 (10223 ): 514-23.
14. Zu ZY, Jiang MD, Xu PPet al (2020). Coronavirus Disease 2019 (COVID-19): A Perspective from China. Radiology, 200490.
15. Dong Y, Mo X, Hu Y et al (2020). Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. Pediatrics, e20200702.
16. Liu J, Zheng X, Tong Q et al (2020). Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS‐CoV, MERS‐CoV, and 2019‐nCoV. J Med Virol, 92(5): 491-4.
17. Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J (2020). The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med, 27(2): taaa021.
18. Society of Pediatrics CMA (2020). Recommendations for the diagnosis, prevention and control of the 2019 novel coronavirus infection in children (first interim edition). Zhonghua Er Ke Za Zhi, 58(0): E004.
19. Zhou S, Wang Y, Zhu T, Xia L (2020). CT Features of Coronavirus Disease 2019 (COVID-19) Pneumonia in 62 Patients in Wuhan, China. AJR Am J Roentgeno,5:1-8.
20. He F, Deng Y, Li W (2020). Coronavirus Disease 2019 (COVID-19): What we know? J Med Virol, 1-7.
21. Lu X, Zhang L, Du H et al (2020). SARS-CoV-2 Infection in Children. N Engl J Med, 2005073.
22. Worcester S (2020). COVID-19 Characteristics Differ in Children vs Adults Available from: https://www.medscape.com/viewarticle/926805
23. Gortazar C, Reperant LA, Kuiken T et al (2014). Crossing the interspecies barrier: opening the door to zoonotic pathogens. PLoS Pathog, 10 (6): e1004129.
24. Rosenberg R (2015). Detecting the emergence of novel, zoonotic viruses pathogenic to humans. Cell Mol Life Sci,72 (6): 1115-25.
25. Brown C (2004). Emerging zoonoses and pathogens of public health significance--an overview. Rev Sci Tech, 23 (2): 435-42.
26. CDC (2017). One Health Basics. Available from: https://www.cdc.gov/onehealth/basics/index.html2017
27. CDC (2016). History. Available from: https://www.cdc.gov/onehealth/basics/history/index.html
28. Bidaisee S, Macpherson CNL (2014). Zoonoses and One Health: A Review of the Literature. J Parasitol Res, 2014: 874345.
29. Wrapp D, Wang N, Corbett KS et al (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 367 (6483): 1260-3.
30. Shi H, Han X, Jiang N et al (2020). Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis, 20: 425-34.
31. Baden LR, Rubin EJ (2020). Covid-19 — The Search for Effective Therapy. N Engl J Med.
32. Gao J, Tian Z, Yang X (2020). Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends, 14 (1): 72-3.
33. Gallardo Solarte K, Benavides Acosta FP, Rosales Jiménez R (2016). Costos de la enfermedad crónica no transmisible: la realidad colombiana. Rev Cienc Salud, 14 (1): 103-14.
34. Maldonado JM (2009). Ciudades y contaminación ambiental. Revista de ingeniería, 30: 66-71.
35. Barrera-Dussán N, Fierro-Parra EP, Puentes-Fierro LY, Ramos-Castañeda JA (2018). Prevalencia y determinantes sociales de malnutrición en menores de 5 años afiliados al Sistema de Selección de Beneficiarios para Programas Sociales (SISBEN) del área urbana del municipio de Palermo en Colombia, 2017. Universidad y Salud, 20 (3): 236-46.
36. Bernal O, Barbosa S (2015). La nueva reforma a la salud en Colombia: el derecho, el aseguramiento y el sistema de salud. Salud Pública Mex, 57 (5): 433-40.
37. Olivera MJ, Porras Villamil JF, Toquica Gahona CC, Rodríguez Hernández JM (2018). Barriers to Diagnosis Access for Chagas Disease in Colombia. J Parasitol Res, 2018: 4940796.
38. Holshue ML, DeBolt C, Lindquist S et al (2020). First case of 2019 novel coronavirus in the United States. N Engl J Med, 382 (10): 929-36.
39. Lim J, Jeon S, Shin H-Y et al (2020). Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci, 35 (6): e79.
| Files | ||
| Issue | Vol 49 No Supple 1 (2020) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijph.v49iS1.3669 | |
| Keywords | ||
| Coronavirus Case reports Public health Pandemic | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
PORRAS-VILLAMIL JF, OLIVERA MJ, RÍOS-CAMARGO NK. The First Few Hundred Cases for Coronavirus Disease 2019 (COVID-19) in Colombia. Iran J Public Health. 2020;49(Supple 1):48-56.
